PRME

Prime Medicine, Inc. Common Stock
Data: 2026-06-23
$3.24
Price
-3.86%
Change
$6.94
52W High
$2.02
52W Low

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Quick Stats
Jun 23, 2026

61.0

AI Score

BUY

1.03

Volume Ratio

Aug 06, 2026

Next Earnings

14

+ve Days (30d)

15

-ve Days (30d)

PRME Stock Summary

Last updated Jun 23, 2026

PRME is currently trading at $3.24, positioned below its 200-day moving average of $3.95, suggesting bearish momentum. The stock has a 52-week range of $2.02 to $6.94.

Technical Analysis: The 50-day moving average stands at $3.3, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 53.003, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.081, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates PRME at 61.0/100 with a BUY recommendation.

PRME (Prime Medicine, Inc. Common Stock) Indicators

Last updated Jun 23, 2026

Indicator Value
RSI(14) 53.003
CMF (20) -0.081
ROC (10) 9.459
ADX (14) 15.755
Indicator Value
MACD (12,26,9) -0.022
AROONOSC (14) -35.714
WILLAMS %R (14) -39.368
MFI (14) 47.567
PRME Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

PRME Price vs Max Options Open Interest
PRME Max Change In Options Open Interest

PRME Options - Sort by Max open Interest (near term)

24th June 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

PRME Daily Out of Money Options - Sort by Max open Interest (near term)

24th June 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

PRME Daily In the Money Options - Sort by Max open Interest (near term)

24th June 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

PRME Most Active Options by Volume(near term)

24th June 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

Prime Medicine, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

PRME Moving Averages Analysis

PRME (Prime Medicine, Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated Jun 23, 2026

Days MA
10 3.0
20 3.12
30 3.08
50 3.3
100 3.48
200 3.95

PRME Fundamental Analysis

P/E (Forward) 0
P/E (Trailing) --
Market Cap ($) 608.7 million
Earnings/Share ($) -1.23
Net Proft Margin (%) 0
Dividend/Share ($) --
EPS Estimate Current Year ($) -0.9847
EPS Estimate Next Year ($) -0.8699
WallStreet Target Price ($) 6.9167
Most Recent Quarter